Completed OBSERVATIONAL NCT05415683

Wound Assessment Using Spectral Imaging US

Sponsor: SpectralMD

Conditions Diabetes Diabetic Foot Diabetic Foot Ulcer

Updated 6 times since 2022 Last updated: Nov 6, 2024 Started: Jun 22, 2022 Primary completion: Jun 28, 2024 Completion: Aug 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05415683, this observational or N/A phase trial focuses on Diabetes and Diabetic Foot and remains completed. Sponsored by SpectralMD, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Dec 2024 — Present [monthly]

Completed

Status: Recruiting → Completed
Sep 2024 — Dec 2024 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Nov 2023 — Jul 2024 [monthly]

Recruiting
Sep 2023 — Nov 2023 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jul 2022 — Sep 2023 [monthly]

Not Yet Recruiting

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SpectralMD

Data source: SpectralMD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Circleville, United States , Encino, United States , Grove City, United States , Hilliard, United States , Lake Success, United States , Los Angeles, United States , Memphis, United States , Mentor, United States , Missouri City, United States , Worthington, United States and 1 more location